SCISPARC LTD

Discover why SciSparc Ltd., a Tel Aviv biotech focused on cannabinoid treatments for CNS disorders, faces sharp stock volatility and negative earnings—and what it could mean for investors.

Explore how SciSparc Ltd. is pioneering cannabinoid tech for CNS disorders—its market dynamics, stock trends, and global impact in biotech.

How SciSparc’s patent‑treasury buy‑out could pivot its Nasdaq stock from niche cannabinoid research to high‑impact CNS endoscopy tech—and what that means for investors.

SciSparc Ltd. (SPRC) stock experienced a 130% price surge due to a merger-related rally, with investors viewing a delay in the merger with AutoMax Motors as a positive development for the company’s growth prospects.